Cervical intraepithelial neoplasia
disease diseaseOn this page
Also known as Cervical Intraepithelial NeoplasmCervical Intraepithelial NeoplasmsIntraepithelial Neoplasia, CervicalIntraepithelial Neoplasm, CervicalIntraepithelial Neoplasms, CervicalNEOPL CERVICAL INTRAEPITHELIALNeoplasia, Cervical IntraepithelialNeoplasm, Cervical IntraepithelialNeoplasms, Cervical Intraepithelial
Summary
Cervical intraepithelial neoplasia (MONDO:0022394) is a disease and 163 clinical trials. Top therapeutic interventions include imiquimod, human papillomavirus, l1 protein virus like particles, and hydroxyzine. A subtype of dysplasia of cervix — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 163
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cervical intraepithelial neoplasia |
| Mondo ID | MONDO:0022394 |
| NCIT | C3782 |
| SNOMED CT | 285636001 |
| UMLS | C0206708 |
| MedGen | 60214 |
| GARD | 0009244 |
| Is cancer (heuristic) | no |
Also known as: Cervical Intraepithelial Neoplasm · Cervical Intraepithelial Neoplasms · Intraepithelial Neoplasia, Cervical · Intraepithelial Neoplasm, Cervical · Intraepithelial Neoplasms, Cervical · NEOPL CERVICAL INTRAEPITHELIAL · Neoplasia, Cervical Intraepithelial · Neoplasm, Cervical Intraepithelial · Neoplasms, Cervical Intraepithelial
Data availability: 5 cell lines.
Disease family
This is a subtype of dysplasia of cervix. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › dysplasia of cervix › cervical intraepithelial neoplasia
Subtypes (2): cervical intraepithelial neoplasia grade 2/3, cervical squamous intraepithelial neoplasia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 163.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 91 |
| PHASE2 | 27 |
| PHASE3 | 17 |
| PHASE1 | 9 |
| PHASE4 | 8 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 3 |
| EARLY_PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05266898 | PHASE4 | RECRUITING | Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV |
| NCT00733109 | PHASE4 | COMPLETED | Management of Cervical Intraepithelial Neoplasia Grade 2 |
| NCT01544478 | PHASE4 | COMPLETED | V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) |
| NCT02368054 | PHASE4 | COMPLETED | Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization |
| NCT02629510 | PHASE4 | UNKNOWN | The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) |
| NCT03105856 | PHASE4 | COMPLETED | FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program |
| NCT03629886 | PHASE4 | COMPLETED | Safety and Protective Effect Study of GSK Biologicals’ Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study |
| NCT05426148 | PHASE4 | COMPLETED | Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female |
| NCT03848039 | PHASE3 | NOT_YET_RECRUITING | Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 |
| NCT04537156 | PHASE3 | ACTIVE_NOT_RECRUITING | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) |
| NCT00156026 | PHASE3 | COMPLETED | Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 |
| NCT00237562 | PHASE3 | COMPLETED | Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit |
| NCT00316706 | PHASE3 | COMPLETED | Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals’ (GSK Bio) HPV-16/18 Vaccine |
| NCT00337818 | PHASE3 | COMPLETED | Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women |
| NCT00941252 | PHASE2/PHASE3 | COMPLETED | ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial |
| NCT00995020 | PHASE3 | COMPLETED | Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion |
| NCT01095198 | PHASE2/PHASE3 | UNKNOWN | Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) |
| NCT01131312 | PHASE3 | COMPLETED | Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) |
| NCT01283763 | PHASE3 | TERMINATED | Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia |
| NCT01735006 | PHASE3 | COMPLETED | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine |
| NCT01929993 | PHASE3 | COMPLETED | A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins |
| NCT02130323 | PHASE2/PHASE3 | COMPLETED | Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix |
| NCT02329171 | PHASE3 | TERMINATED | Imiquimod Treatment of CIN Lesions |
| NCT02562508 | PHASE3 | COMPLETED | A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls |
| NCT02669459 | PHASE3 | UNKNOWN | Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol |
| NCT02733068 | PHASE3 | COMPLETED | A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. |
| NCT03355820 | PHASE3 | COMPLETED | A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals’ HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study |
| NCT04646954 | PHASE3 | UNKNOWN | DNA Methylation Testing for the Screening of Uterine Cervical Lesion |
| NCT04712851 | PHASE2 | RECRUITING | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia |
| NCT06525870 | PHASE2 | ENROLLING_BY_INVITATION | Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial |
| NCT00154089 | PHASE1/PHASE2 | COMPLETED | A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia |
| NCT00190983 | PHASE2 | COMPLETED | A Trial for Patients With Advanced/Recurrent Cervical Cancer |
| NCT00247169 | PHASE2 | COMPLETED | Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II |
| NCT00285207 | PHASE2 | COMPLETED | Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix |
| NCT00596258 | PHASE2 | COMPLETED | A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) |
| NCT00708942 | PHASE2 | TERMINATED | Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 |
| NCT01022346 | PHASE2 | COMPLETED | A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection |
| NCT01116245 | PHASE2 | TERMINATED | An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ |
| NCT01256424 | PHASE2 | COMPLETED | Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia |
| NCT01304524 | PHASE2 | COMPLETED | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| IMIQUIMOD | 4 | 7 |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | 4 | 3 |
| HYDROXYZINE | 4 | 3 |
| LOPERAMIDE | 4 | 3 |
| PROCHLORPERAZINE | 4 | 3 |
| ATROPINE SULFATE | 4 | 1 |
| BUPIVACAINE | 4 | 1 |
| CODEINE SULFATE | 4 | 1 |
| DIPHENHYDRAMINE HYDROCHLORIDE | 4 | 1 |
| DIPHENOXYLATE HYDROCHLORIDE | 4 | 1 |
| DROPERIDOL | 4 | 1 |
| EPINEPHRINE | 4 | 1 |
| GRANISETRON | 4 | 1 |
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | 4 | 1 |
| HEXAMINOLEVULINATE | 4 | 1 |
| INDOMETHACIN | 4 | 1 |
| MEPERIDINE | 4 | 1 |
| HILTONOL | 2 | 1 |
| SIVIFENE | 2 | 1 |
| TERAMEPROCOL | 2 | 1 |
| TIPAPKINOGENE SOVACIVEC | 2 | 1 |
| VERPASEP CALTESPEN | 2 | 1 |
| CHEMBL284671 | 0 | 1 |
| CHEMBL399538 | 0 | 1 |
Related Atlas pages
- Drugs: Imiquimod, HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES, Hydroxyzine, Loperamide, Prochlorperazine, Atropine, Bupivacaine, Codeine, Diphenhydramine, Diphenoxylate, Droperidol, Epinephrine, Granisetron, Hepatitis B Virus Hbsag Surface Protein Antigen, Hexaminolevulinate, Indomethacin, Meperidine